The pace of innovation in the Life Sciences field is accelerating, and the regulatory oversight of the resulting products and ...

Discover why CLLS is a top speculative Buy, with promising CAR-T therapies, strong big pharma partnerships, and attractive ...

Scientists in China have genetically engineered a fungus that is widely used as a meat substitute, making it an even more ...

From rare diseases to chronic conditions, epigenetic editing unlocks new ways to control gene activity without altering the genetic code.

Gain insights into the U.S. market, valued at $5.9 Billion in 2024, and China, forecasted to grow at an impressive 14.4% CAGR to reach $7.8 Billion by 2030. Discover growth trends in other key regions ...

CRISPR Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 82.

Poster presentation highlights promising results from Phase 1b/2 TENACITY-01 study of CTD402 in T-Cell and myeloid leukemiasFindings underscore ...

Flashpoint Therapeutics, a biotechnology company pioneering a new class of structural nanomedicines, today congratulates its scientific co-founder, Professor Chad A. Mirkin, on being awarded the ...

Data Demonstrate Potent in vivo Gene Editing of Hematopoietic Stem Cells (HSCs) in the Bone Marrow with Systemic Delivery in Preclinical Murine ...

The United States DNA polymerase market is projected to reach USD 246.9 million by 2035, supported by rising investments in ...

Both stocks are risky, but one is far less so. This juicy upside potential comes at a cost. Investors seeking stocks with ...